Literature DB >> 15876188

Activation of RelA homodimers by tumour necrosis factor alpha: a possible transcriptional activator in human vascular endothelial cells.

Nobuyuki Marui1, Russell M Medford, Mushtaq Ahmad.   

Abstract

In vascular endothelial cells, cytokines induce genes that are expressed in inflammatory lesions partly through the activation of transcription factor NF-kappaB (nuclear factor-kappaB). Among the members of the NF-kappaB/rel protein family, homodimers of the RelA subunit of NF-kappaB can also function as strong transactivators when expressed in cells. However, the functional role of endogenous RelA homodimers has not been clearly elucidated. We investigated whether RelA homodimers are induced in cytokine-treated vascular endothelial cells. Gel mobility-shift and supershift assays revealed that a cytokine TNFalpha (tumour necrosis factor alpha) activated both NF-kappaB1/RelA heterodimers and RelA homodimers that bound to a canonical kappaB sequence, IgkappaB (immunoglobulin kappaB), in SV40 (simian virus 40) immortalized HMEC-1 (human dermal microvascular endothelial cell line 1). In HMEC-1 and HUVEC (human umbilical-vein endothelial cells), TNFalpha also induced RelA homodimers that bound to the sequence 65-2kappaB, which specifically binds to RelA homodimers but not to NF-kappaB1/RelA heterodimers in vitro. Deoxycholic acid, a detergent that can dissociate the NF-kappaB-IkappaB complex (where IkappaB stands for inhibitory kappaB), induced the binding of the RelA homodimers to 65-2kappaB from the cytosolic fraction of resting HMEC-1. Furthermore, TNFalpha induced the transcriptional activity of a reporter gene that was driven by 65-2kappaB in HMEC-1. These results suggest that in addition to NF-kappaB1/RelA heterodimers, TNFalpha also induces RelA homodimers that are functionally active. Thus RelA homodimers may actively participate in cytokine regulation of gene expression in human vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876188      PMCID: PMC1184585          DOI: 10.1042/BJ20041659

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  55 in total

Review 1.  The inducible transcription activator NF-kappa B: regulation by distinct protein subunits.

Authors:  P A Baeuerle
Journal:  Biochim Biophys Acta       Date:  1991-04-16

2.  Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B.

Authors:  S M Ruben; P J Dillon; R Schreck; T Henkel; C H Chen; M Maher; P A Baeuerle; C A Rosen
Journal:  Science       Date:  1991-03-22       Impact factor: 47.728

3.  RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B.

Authors:  R P Ryseck; P Bull; M Takamiya; V Bours; U Siebenlist; P Dobrzanski; R Bravo
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

4.  Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B.

Authors:  T Fujita; G P Nolan; S Ghosh; D Baltimore
Journal:  Genes Dev       Date:  1992-05       Impact factor: 11.361

5.  DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide.

Authors:  G P Nolan; S Ghosh; H C Liou; P Tempst; D Baltimore
Journal:  Cell       Date:  1991-03-08       Impact factor: 41.582

6.  An NF kappa B-like factor is essential but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription.

Authors:  J Whelan; P Ghersa; R Hooft van Huijsduijnen; J Gray; G Chandra; F Talabot; J F DeLamarter
Journal:  Nucleic Acids Res       Date:  1991-05-25       Impact factor: 16.971

7.  Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation.

Authors:  N D Perkins; R M Schmid; C S Duckett; K Leung; N R Rice; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

8.  The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression.

Authors:  D W Ballard; E P Dixon; N J Peffer; H Bogerd; S Doerre; B Stein; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B.

Authors:  M L Schmitz; P A Baeuerle
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.

Authors:  R Schreck; B Meier; D N Männel; W Dröge; P A Baeuerle
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

View more
  4 in total

1.  Association of growth factors, HIF-1 and NF-κB expression with proteasomes in endometrial cancer.

Authors:  Ludmila V Spirina; Nataliya V Yunusova; Irina V Kondakova; Larisa A Kolomiets; Valeriya D Koval; Alena L Chernyshova; Olga V Shpileva
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

2.  Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities.

Authors:  Liudmila V Spirina; Irina V Kondakova; Evgeny L Choynzonov; Svetlana Y Chigevskaya; Dmitry A Shishkin; Denis Y Kulbakin
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-27       Impact factor: 4.553

3.  Similar NF-κB gene signatures in TNF-α treated human endothelial cells and breast tumor biopsies.

Authors:  Martine Perrot-Applanat; Sophie Vacher; Aurore Toullec; Irma Pelaez; Guillaume Velasco; Françoise Cormier; Hanan El Sheikh Saad; Rosette Lidereau; Véronique Baud; Ivan Bièche
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

4.  Canonical NF-κB p65, but Not p105, Contributes to IL-1β-Induced IL-8 Expression in Cardiac Fibroblasts.

Authors:  Masashi Mizuno; Rei Nakano; Saki Nose; Moeka Matsumura; Yasuyuki Nii; Kentaro Kurogochi; Hiroshi Sugiya; Masami Uechi
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.